Literature DB >> 3379586

Glycolamide esters as biolabile prodrugs of carboxylic acid agents: synthesis, stability, bioconversion, and physicochemical properties.

N M Nielsen1, H Bundgaard.   

Abstract

Benzoic acid esters of various substituted 2-hydroxyacetamides (glycolamides) were found to be hydrolyzed extremely rapidly in human plasma solutions, the half-lives of hydrolysis being less than 5 s in 50% plasma solutions for some N,N-disubstituted glycolamide esters. The rapid rate of hydrolysis could be largely attributed to cholinesterase (also called pseudocholinesterase) present in plasma. From a study of a variety of substituted glycolamide esters and structurally related esters, the most prominent structural requirement needed for a rapid rate of hydrolysis was found to be the glycolamide ester structure combined with the presence of two substituents on the amide nitrogen atom. A structural similarity of such esters with benzoylcholine, a good substrate for cholinesterase, was put forward. Esters of N,N-disubstituted glycolamides are suggested to be a useful biolabile prodrug type for several carboxylic acid agents. The esters combine a high susceptibility to undergo enzymatic hydrolysis in plasma with a high stability in aqueous solution. Furthermore, as demonstrated with the benzoic acid model esters, it is feasible to obtain ester derivatives with almost any desired water solubility or lipophilicity with retainment of marked lability to enzymatic hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379586     DOI: 10.1002/jps.2600770402

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Synthesis and biological evaluation of omega-(N,N,N-trialkylammonium)alkyl esters and thioesters of carboxylic acid nonsteroidal antiinflammatory agents.

Authors:  M C Venuti; J M Young; P J Maloney; D Johnson; K McGreevy
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

2.  Acyloxymethyl as a drug protecting group: Part 4. The hydrolysis of tertiary amidomethyl ester prodrugs of carboxylic acid agents.

Authors:  J Iley; R Moreira; T Calheiros; E Mendes
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

3.  Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis.

Authors:  Yan Yan; Jinyao Sun; Xianting Xie; Pengchong Wang; Ying Sun; Yalin Dong; Jianfeng Xing
Journal:  RSC Adv       Date:  2018-01-11       Impact factor: 4.036

4.  1-[2-(4-Isobutyl-phen-yl)propano-yl]thiosemicarbazide.

Authors:  Hoong-Kun Fun; Reza Kia; Samuel Robinson Jebas; K V Sujith; B Kalluraya
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-02-28

5.  Bioreversible derivatives of phenol. 1. The role of human serum albumin as related to the stability and binding properties of carbonate esters with fatty acid-like structures in aqueous solution and biological media.

Authors:  Jesper Østergaard; Claus Larsen
Journal:  Molecules       Date:  2007-10-30       Impact factor: 4.411

6.  Stereoselective enzymatic hydrolysis of various ester prodrugs of ibuprofen and flurbiprofen in human plasma.

Authors:  N Mørk; H Bundgaard
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

7.  Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases.

Authors:  Jing Fu; Erik Pacyniak; Marina G D Leed; Matthew P Sadgrove; Lesley Marson; Michael Jay
Journal:  J Pharm Sci       Date:  2016-01-12       Impact factor: 3.534

8.  Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.

Authors:  Morten Rohde; Niels M Rk; Anders E Håkansson; Klaus G Jensen; Henrik Pedersen; Tina Dige; Erling B J Rgensen; René Holm
Journal:  Results Pharma Sci       Date:  2014-05-02

9.  Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data.

Authors:  L T Baxter; R K Jain
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.